All In Biotech

Drug Trial Radar · NCT04645069

ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

A First-in-Human (FIH), Open-Label, Phase 1/2 Dose Escalation and Expansion Study of ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Patients With Advanced/Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

58

Actual

Start

Mar 15, 2021

Primary completion

Jan 29, 2024

Study completion May 17, 2024

Sponsor

Lead sponsor
Adagene IncIndustry
Sponsor type
Industry
First posted
Nov 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ADG126, ADG126 in Combination with anti-PD1 antibody, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors .

Conditions

  • Advanced/Metastatic Solid Tumors

Interventions

  • ADG126 MonoBiological

    ADG126 will be administered as an IV infusion over 30-60 minutes ± 15 minutes.

  • ADG126-anti PD1Biological

    ADG126-toripalimab combination regimen will receive of toripalimab 15 to 30 minutes after the end of the ADG126 infusion

  • ADG126-ADG106Biological

    ADG126-ADG106 combination regimen will be receive of ADG106 15 to 30 minutes after the end of the ADG126 infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants experiencing dose-limiting toxicities escalating dose levels in adults with advanced / metastatic solid tumorsTime frame: From first dose of ADG126 (Week 1 Day 1) until 21 days
  2. Number of participants with adverse events as assessed by CTCAE v5.0 ADG126-ADG106 combination regimensTime frame: From first dose of ADG126 (Week 1 Day 1) to 90 days post last dose

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles

    Los Angeles, California

  • Next oncology

    San Antonio, Texas

  • Southside Cancer Care Centre

    Miranda, New South Wales, Australia

  • Macquarie University Hospital

    Sydney, New South Wales, Australia

  • Sunshine Coast University Private Hospital

    Birtinya, Queensland, Australia

  • Cabrini Health Limited

    Malvern, Victoria, Australia

  • One Clinical Research Pty Ltd

    Nedlands, Western Australia, Australia

  • National University Hospital

    Singapore, Singapore

  • National Cancer Centre Singapore

    Singapore, Singapore

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.